Peringkat dalam Saham
#12599
CTI BioPharma Corp. is a biopharmaceutical company dedicated to the discovery,... CTI BioPharma Corp. is a biopharmaceutical company dedicated to the discovery, advancement, and commercialization of innovative, targeted treatments for blood cancers within the United States. Its key product is VONJO (pacritinib), an oral kinase inhibitor currently under investigation, specifically designed to target JAK2, FLT3, IRAK1, and CSF1R for the management of adult patients with myelofibrosis. The company holds licensing and collaboration agreements with Teva Pharmaceutical Industries Ltd., SBIO Pte Ltd., and Baxalta. Established in 1991 and based in Seattle, Washington, CTI BioPharma Corp. was previously known as Cell Therapeutics, Inc., adopting its current name in May 2014.
Harga Saham
$9.09
Terakhir disinkronkan: 2023-06-23
Kapitalisasi Pasar
$567.77M
Perubahan (1 tahun)
0.00%
Perdagangan CTI BioPharma Corp. (CTIC)
Harga CTIC dengan kapitalisasi pasar B
Kapitalisasi pasar dari CTI BioPharma Corp.(CTIC)
Kapitalisasi Pasar: $567.77M
Per August 2026, CTI BioPharma Corp. memiliki kapitalisasi pasar sebesar $567.77M. Ini menjadikan CTI BioPharma Corp. sebagai perusahaan 12599th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar CTI BioPharma Corp. dari 1997 hingga 2026
CTIC dibandingkan dengan 5 teratas stocks paling populer
| Harga CTIC |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.264T
|
+927,011.86%
|
|
|
|
|
$4.701T
|
+827,923.98%
|
|
|
|
|
$4.177T
|
+735,615.87%
|
|
|
|
|
$3.817T
|
+672,249.31%
|
|
|
|
|
$2.866T
|
+504,740.75%
|
